For 2018, CIBC World Markets is recommending investors hold a basket of healthcare stocks that include a combination of more speculative small and midcap companies with selected large caps.Read More
Synergy CHC (OTCQB:SNYR) appointed Jeffrey Kadanoff as its CFO, effective Nov, 1, 2017.Read More
Knight Therapeutics’ (TSX:GUD) New Drug Submission (NDS) for Probuphine, a subdermal implant of buprenorphine for the treatment of opioid drug dependence, has been accepted for review by Health Canada.Read More
3D Signatures (TSX-V:DXD) has appointed Joost van der Mark as its chief business officer, effective Jan. 6.Read More
Knight Therapeutics (TSX:GUD) has closed on a $1-million equity investment in closely-held 3D Signatures, which has completed a business combination and public listing transaction.
3D is a personalized medicine company, with a proprietary software platform based on the three-dimensional analysis of telomere organization. The technology is supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease.Read More
Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive rights to commercialize Titan’s Probuphine in Canada.
Probuphine is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention, as well as helping to prevent accidental pediatric exposure.Read More